Health Care & Life Sciences » Biotechnology | Achillion Pharmaceuticals Inc.

Achillion Pharmaceuticals Inc. | Ownership

Companies that own Achillion Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
RTW Investments LP
13,541,997
9.77%
45,095
2.68%
06/30/2018
The Vanguard Group, Inc.
10,984,957
7.93%
264,504
0%
06/30/2018
BlackRock Fund Advisors
10,748,713
7.76%
235,829
0%
06/30/2018
Dimensional Fund Advisors LP
6,892,184
4.97%
849,721
0.01%
06/30/2018
SSgA Funds Management, Inc.
6,027,239
4.34%
109,374
0%
06/30/2018
Citadel Advisors LLC
4,679,824
3.38%
1,805,261
0.02%
06/30/2018
T. Rowe Price Associates, Inc.
4,579,073
3.3%
-79,883
0%
06/30/2018
Goldman Sachs & Co. LLC (Private Banking)
4,227,834
3.05%
-114,791
0.01%
06/30/2018
Armistice Capital LLC
4,000,000
2.89%
-296,000
1.05%
06/30/2018
Ecor1 Capital LLC
3,887,407
2.81%
219,100
1.39%
06/30/2018

About Achillion Pharmaceuticals

View Profile
Address
VEVA Building 14
Blue Bell Pennsylvania 19422
United States
Employees -
Website http://www.achillion.com
Updated 07/08/2019
Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.